Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BL-B01D1 + Osimertinib vs Osimertinib in Stage III EGFR-mutated NSCLC (PANKU-Lung08)
NCT07640789Phase 3Recruiting
- Sponsor
- Biokin Pharmaceutical
- Start
- Aug 2026
- Primary completion
- Dec 2030
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of izalontamab brengitecan in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Biokin Pharmaceutical. Primary endpoint: Progression-Free Survival at 24 months. Started Aug 2026; status: recruiting.
02
Drugs
izalontamab brengitecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07640789.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07640789.